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1.1. Document Development Process
The Society of Pediatric Cardiology Training Program
Directors (SPCTPD) board assembled a Steering Com-
mittee that nominated 2 chairs, 1 SPCTPD Steering
Committee member, and 5 additional members from a
wide range of program sizes, geographic regions, and
subspecialty focuses. Representatives from the Amer-
ican College of Cardiology (ACC), American Academy of
Pediatrics (AAP), and American Heart Association
(AHA) participated. The Steering Committee member
was added to provide perspective to each Task Force
as a “nonexpert” in that ﬁeld. Relationships with
industry and other entities were not deemed relevant
to the creation of a general cardiology training
statement; however, employment and afﬁliation in-l
-
,
-
,
-
/formation for authors and peer reviewers are provided
in Appendixes 1 and 2, respectively, along with
disclosure reporting categories. Comprehensive dis-
closure information for all authors, including re-
lationships with industry and other entities, is
available as an online supplement to this document.
The writing committee developed the document,
approved it for review by individuals selected by
the participating organizations (Appendix 2), and
addressed their comments. The ﬁnal document was
approved by the SPCTPD, AAP, and AHA in February
2015 and approved by the ACC in March 2015. This
document is considered current until the SPCTPD
revises or withdraws it.
1.2. Background and Scope
The availability of effective pharmacological and
surgical treatments for children with pulmonary hy-
pertension (PH) or advanced heart failure has grown
rapidly over the past decade (1-3). Although the care
of children with these diseases is often coordinated
by specialized centers, pediatric cardiologists are
increasingly called upon to evaluate and participate in
the care of children with PH or advanced heart failure
and those who have undergone thoracic organ trans-
plantation. Thus, core training in pediatric cardiology
must include sufﬁcient clinical exposure and didactic
opportunities for the trainee to gain competency
in the evaluation and management of children with
these diseases. In addition, for the general pediatric
cardiologist to counsel patients and make appropriate
referrals, core training must include exposure to
key concepts in advanced care of these diseases,
including the indications, risks, and beneﬁts of
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733pulmonary vasodilator therapy, mechanical circulatory
support, and heart, lung, or heart–lung transplantation
(3). The requirements for core training in PH and
advanced heart failure for all trainees seeking board cer-
tiﬁcation in pediatric cardiology are outlined in the next
sections. Advanced requirements are much more
comprehensive, require a dedicated period of training,
and apply only to practitioners planning to subspecialize
in the care of children with these diseases.
Our revised training recommendations describe the
program resources and environment that are required for
training pediatric cardiology fellows, together with a
competency-based system promulgated by the Accredi-
tation Council of Graduate Medical Education (ACGME),
to implement speciﬁc goals and objectives for training
pediatric cardiology fellows. This system categorizes
competencies into 6 core competency domains: Medi-
cal Knowledge, Patient Care and Procedural Skills,
Systems-Based Practice, Practice-Based Learning and
Improvement, Professionalism, and Interpersonal and
Communication Skills, along with identiﬁcation of sug-
gested evaluation tools for each domain. Core compe-
tencies unique to pediatric PH and heart failure are listed
in Sections 2.2 and 3.2, respectively (see the “2015
SPCTPD/ACC/AAP/AHA Training Guidelines for Pediatric
Cardiology Fellowship Programs [Revision of the 2005
Training Guidelines for Pediatric Cardiology Fellowship
Programs]: Introduction” for additional competencies
that apply to all Task Force reports).
1.3. Levels of Expertise—Core and Advanced
Core training must be available at all centers with a
fellowship program in pediatric cardiology. The core cur-
riculum described in Sections 2.2 (PH) and 3.2 (heart fail-
ure) is intended to be sufﬁcient for fellows who do not plan
a formal career in PH, advanced heart failure, or cardiac
transplantation. Core training is required for all trainees
and is intended to ensure that fellows acquire the knowl-
edge base and skills necessary to become a pediatric
cardiologist referring his/her patient for specialized care in
these areas. Advanced training guidelines are recom-
mended for fellows whowish to specialize in PH, advanced
heart failure, and cardiac transplantation training.
Advanced training should only take place at select centers
with a sufﬁcient patient volume that prepares the trainee
for clinical practice involving invasive procedures.
2. PULMONARY HYPERTENSION
2.1. Program Resources and Environment
Training in PH should be performed in a program
approved by the ACGME. The pediatric faculty respon-
sible for teaching this curriculum should have expertise in
PH, critical care medicine, neonatal medicine, cardiology,echocardiography, cardiac catheterization, genetics, and
pulmonary medicine. In some centers, the primary ser-
vice caring for PH patients will be the pulmonary service;
thus, training may occur under the supervision of the
pulmonary medicine service. Trainees optimally will
participate in evaluation and treatment in multiple inpa-
tient and outpatient settings. The following are venues
for providing care in pediatric PH: the outpatient clinic,
consultation service, ward and intensive care units
(pediatric and neonatal), noninvasive imaging laboratory,
and cardiac catheterization laboratory.
2.2. Core Training: Goals and Methods
In formulating core training requirements, it is expected
that all board-certiﬁed pediatric cardiologists should be
able to: 1) perform the initial evaluation and manage-
ment of the child with PH in the outpatient ambulatory
setting; 2) perform the initial evaluation and stabiliza-
tion of the hemodynamically compromised patient with
PH; 3) understand the indications, risks, and beneﬁts of
medications used for the treatment of PH; and 4) un-
derstand the indications and appropriate timing of
referral to a dedicated specialist in pediatric or adult PH
for advanced care.
2.2.1. General Requirements
At the end of the 3-year pediatric cardiology fellowship,
the board-eligible pediatric cardiologist should be able to
evaluate and provide the initial treatment of neonates,
infants, children, and adolescents with PH of various
etiologies described in Table 1. Suggested evaluation tools
to assess competence are denoted in the table.
2.2.2. Speciﬁc Areas of Knowledge and Competence
The board-eligible pediatric cardiologist should have
knowledge in the following areas of PH physiology,
evaluation, and treatment and be able to apply speciﬁc
knowledge to the care of an infant, child, and adolescent
with PH.
2.2.2.1. Physiology
n Normal pulmonary vascular physiology, including the
“neonatal transition” in pulmonary vascular resistance
n Distinction between PH and elevated pulmonary
vascular resistance (i.e., hypertensive pulmonary vas-
cular disease)
n Pulmonary vascular pathophysiology, including the
physiological and clinical meaning of “reactivity” to
vasodilators as reactivity relates to suitability for sur-
gical repair as opposed to indications for calcium
channel blocker therapy in the outpatient setting
n Indications/contraindications for repair of congenital
cardiac lesions in the presence of pulmonary vascular
disease
TABLE 1 Core Curricular Competencies and Evaluation Tools for Pediatric PH
Medical Knowledge
n Know the difference between PH and PAH.
n Know the use of FDA-approved medications in adults with PAH and medications commonly used in pediatric patients with PAH, including understanding
of important drug interactions and adverse effects of medications.
n Know the indications, risks, beneﬁts, and outcomes of lung or heart–lung transplantation in children with PH.
Evaluation Tools: direct observation, conference participation and presentation, procedure logs, and in-training examination
Patient Care and Procedural Skills
n Have the skills to identify the common presenting clinical features of PH.
n Have the skills to interpret pertinent ﬁndings on echocardiogram for patients with PH.
n Have the skills to perform key components of an initial evaluation of PH that is due to multiple etiologies, including: persistent PH of the
newborn, congenital heart disease (including Eisenmenger physiology), PH associated with left heart disease, PH associated with chronic lung
disease, and idiopathic PAH.
n Have the skills to plan an appropriate referral for consultation with a dedicated specialist in pediatric or adult PH.
n Have the skills to apply available outcome data for children treated with targeted PH therapy to the care of a patient with PH.
n Have the skills to counsel families regarding the acute and chronic care of the child with PH.
Evaluation Tools: direct observation, conference participation, and procedure logs
FDA indicates U.S. Food and Drug Administration; PAH, pulmonary artery hypertension; and PH, pulmonary hypertension.
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734n Normal right ventricular function, as well as acute and
chronic right ventricular dysfunction
n Interactions and relationships between the right and
left ventricles in normal physiology and in the setting
of pulmonary vascular diseases
n Pathophysiology of congenital heart disease with
intracardiac or arterial level shunt, including Eisen-
menger physiology
n Physiology of the patient with pulmonary artery hy-
pertension (PAH) that is due to pulmonary venous
hypertension
2.2.2.2. Clinical Evaluation, Imaging, and Hemodynamics
n Identify the common presenting symptoms and phys-
ical examination ﬁndings in patients with PH with
and without congenital heart disease.
n Identify the common presenting signs and symptoms
of right and left heart failure.
n Indications, risks, and beneﬁts of techniques com-
monly used to evaluate patients with PH, including
electrocardiography, echocardiography, cardiac mag-
netic resonance imaging, cardiac computed tomogra-
phy, ventilation, and perfusion lung scans
n Indications, risks, and beneﬁts of cardiac catheteriza-
tion and vasodilator testing
2.2.2.3. Classiﬁcation
n Understand the World Health Organization Classiﬁca-
tion of PH.
2.2.2.4. Genetics
n Understand patterns of heritable PAH.
n Understand genetic tests relevant to heritable PH.
2.2.2.5. Treatment
n Cardiovascular pharmacology. Understand the indi-
cations, mechanisms of action, appropriate routes of
administration, and adverse effects of the followingmedications used to treat PAH and understand the
potential drug–drug interactions between the speciﬁc
PAH therapies and other medications used to treat PAH.
Currently relevant medications include:
n PDE-5 inhibitors (sildenaﬁl, tadalaﬁl)
n Endothelin receptor antagonists (bosentan, ambri-
sentan, macitentan)
n Prostacyclin analogues (epoprostenol, treprostinil,
iloprost)
n Inhaled nitric oxide
n Diuretics
n Warfarin
n Soluble guanylate cyclase stimulators (riociguat)
n Indications, risks, beneﬁts, and outcomes of short- and
long-term mechanical circulatory support in the treat-
ment of patients with PH, including extracorporeal
membrane oxygenator and ventricular assist devices
n Indications, risks, beneﬁts, and outcomes of lung or
heart lung transplantation in the treatment of patients
with PH
2.2.3. Evaluation and Documentation of Competence
All training programs should include written goals and
objectives for evaluation and care of patients with PH
with performance goals set according to the fellow’s level
of training. These will serve as the basis for formative
feedback. A copy of these goals and objectives should be
supplied and explained to the trainee at the onset of
fellowship training and reviewed at the beginning of each
year. Evaluation of fellows should be performed midway
through, and at the completion of, each rotation; evalu-
ations should be directed toward whether the fellow met
those prespeciﬁed aims. The fellow evaluation should
assess the fellow’s performance in each of the 6 areas of
core competencies, as appropriate for the level of
training, and should be based on direct observation of the
fellow. Evaluation of competency in preparation, perfor-
mance, and interpretation of the results of a procedure
should be given more consideration than a focus on the
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tency should be done in person with the trainee and
documented in the fellowship record. If the trainee is not
progressing as expected, remedial actions should be ar-
ranged and documented in accordance with institutional
procedures. All fellows should maintain a log (preferably
electronic) of all PH patients. Trainees should participate
in diagnosis and treatment of a minimum of 20 patients
(10 inpatient and 10 outpatient) during the 3 years of
training to ensure adequate clinical exposure and enable
sufﬁcient opportunities for assessment by the clinical
competency committees and their program directors.
2.3. Advanced Training: Goals and Methods
Advanced trainees in PAH require a dedicated 6- to
12-month time period working with a comprehensive
pediatric PH program. All advanced trainees should have
a rigorous (bench, clinical, or translational) research
training experience pertinent to PH as part of (or prior to)
their advanced training.
At the completion of the advanced training fellowship,
the trainee should undergo a competency assessment
that establishes the ability to independently perform a
comprehensive evaluation of a patient with PH. The
trainee should be able to formulate and execute a treat-
ment plan based on the evaluation in conjunction with a
PH subspecialist. Clinical competence should be assessed
using a combination of direct observation of clinical per-
formance and structured interviews by a PH subspecialist.3. ADVANCED HEART FAILURE
3.1. Program Resources and Environment
Training in pediatric heart failure and transplantation
should be performed in a program approved by the
ACGME. Although not all programs will have a dedicated
team for the management and treatment of advanced
pediatric heart failure and transplantation, clinical
expertise can be found in the subspecialties of general
cardiology, noninvasive imaging, cardiac catheterization,
electrophysiology, critical care, neonatology, cardiotho-
racic surgery, and genetics. Training programs should
have a relationship with a center that provides advanced
heart failure care (ventricular assist devices and trans-
plantation). Faculty from these specialized centers may
enhance fellowship training by providing didactics or
clinical experience in advanced heart failure and trans-
plantation. Trainees should participate in the treatment
of patients with heart failure and transplantation, in-
cluding the evaluation and treatment in multiple inpa-
tient and outpatient settings. The following are venues
for providing training in pediatric heart failure and
transplantation: the outpatient clinic, the consultationservice, the ward and the intensive care unit, and the
noninvasive and cardiac catheterization laboratory.3.2. Core Training: Goals and Methods
In formulating the core training requirements, it is ex-
pected that all board-certiﬁed pediatric cardiologists
would be proﬁcient in the following: 1) evaluation and
treatment of the ambulatory child with heart failure;
2) initial evaluation and stabilization of the hemody-
namically compromised patient with heart failure; 3)
administration of medications approved or commonly
used for the treatment of heart failure; 4) appropriate
referral to dedicated specialist for consideration of
advanced management options, including mechanical
circulatory support and transplantation evaluation; and
5) shared cardiology care, with a specialized center, of a
recipient who has undergone transplantation (4,5).
3.2.1. General Requirements
At the end of the 3-year pediatric cardiology fellowship,
the board-eligible pediatric cardiologist should be able to
perform the competencies shown in Table 2. Suggested
evaluation tools to assess competence are denoted in
the table.
3.2.2. Speciﬁc Areas of Knowledge and Competence
The board-eligible pediatric cardiologist will have the
following areas of knowledge and be able to apply the
knowledge to the care of an infant, child, or adolescent
with heart failure:
3.2.2.1. Physiology
n Understand the pathophysiology of heart failure in
children with congenital and acquired heart diseases.
n Recognize the impact of the systolic and diastolic func-
tion of the left and right ventricles on cardiac output.
n Understand the interactions and relationships between
the right and left ventricles in normal physiology and
in the setting of congenital heart disease and
cardiomyopathies.
n Understand the effect of congenital heart defects on
the manifestations of heart failure.3.2.2.2. Diagnostic Techniques
n Recognize the symptoms and identify the signs of heart
failure, including right-sided congestion, pulmonary
overcirculation and edema, low cardiac output, and
rhythm disorders.
n Interpret results of noninvasive techniques commonly
used to evaluate patients with heart failure (e.g., bio-
markers, echocardiography, exercise testing, cardiac
magnetic resonance imaging).
TABLE 2 Core Curricular Competencies and Evaluation Tools for Advanced Pediatric Heart Failure
Medical Knowledge
n Know the signs and symptoms of heart failure in children.
n Know the role of extracorporeal membrane oxygenator support, ventricular assist device support, and transplantation in the treatment of
end-stage heart failure.
n Know the indications, mechanism of actions, risks, and beneﬁts associated with the FDA-approved medications for use in adults with heart
failure and medications commonly used in pediatric patients with heart failure.
Evaluation Tools: direct observation, conference participation and presentation, procedure logs, and in-training examination
Patient Care and Procedural Skills
n Have the skills to evaluate and provide initial treatment for pediatric patients with heart failure of various etiologies.
n Have the skills to develop a differential diagnosis in a child with heart failure.
n Have the skills to establish an accurate diagnosis for the child with heart failure utilizing noninvasive imaging, genetic evaluation, endomyocardial biopsy,
and cardiac catheterization.
n Have the skills to evaluate the clinical condition of the heart failure patient and interpret the results of arrhythmia testing, exercise testing, biomarker
levels, noninvasive imaging, and cardiac catheterization to plan the appropriate treatment.
n Have the skills to initiate medical therapies to treat heart failure, including anticongestive medications, antiarrhythmic medications, inotropic support,
and neurohormonal blockade (e.g., angiotensin-converting enzyme inhibitors, beta-blockers).
n Have the skills to plan appropriate consultation with a dedicated specialist in pediatric advanced heart failure therapies.
Evaluation Tools: direct observation, conference participation, and procedure logs
FDA indicates U.S. Food and Drug Administration.
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736n Know the indications, risks, and beneﬁts of cardiac
catheterization and endomyocardial biopsy in the eval-
uation of children with heart failure or cardiomyopathy.
n Know the hemodynamic ﬁndings associated with sys-
tolic and diastolic heart failure.
n Know how to evaluate pulmonary vascular resistance in
heart failure patients.
n Understand the uses and limitations of serial moni-
toring with currently available biomarkers for heart
failure.
3.2.2.3. Cardiovascular Pharmacology
The trainee should learn mechanisms, indications for use,
and side effects of pharmacologic agents used to treat
pediatric heart failure:
n Diuretics
n Inotropic agents
n Vasodilators
n Vasoconstrictors
n Inhaled nitric oxide
n Anticoagulants
n Antiarrhythmics
n Neurohormonal blockade
n Cardiac glycosides
3.2.2.4. Classiﬁcation (6,7)
n Know the common classiﬁcations of cardiomyopathies
(e.g. morphological, genetic, physiological).
n Know the clinical classiﬁcations of heart failure
commonly used in children and know the stages of
heart failure.3.2.2.5. Arrhythmia Management
n Identify the arrhythmias associated with heart failure.
n Plan the pharmacological management of arrhythmias.n Understand the indications, risks, and beneﬁts of
implantable deﬁbrillator and resynchronization therapy.
3.2.2.6. Mechanical Circulatory Support (8)
n Know the indications, risks, and beneﬁts of extracor-
poreal membrane oxygenator support and ventricular
assist devices.
n Understand the physiology of extracorporeal membrane
oxygenator support and ventricular assist devices.
n Know the outcomes of extracorporeal membrane
oxygenation and mechanical circulatory support in
heart failure.
3.2.2.7. Understand the Consensus Guidelines for
the Treatment of Heart Failure
n 2013 ACCF/AHA Guideline for the Management of Heart
Failure (9)
n ISHLT: Practice Guidelines for Management of Heart
Failure in Children (4)
3.2.2.8. Heart Transplantation (10,11)
n Know the outcomes of heart transplantation, including
mortality and major morbidities.
n Know the indications and contraindications for heart
transplantation.
n Know the incidence of the common complications
associated with heart transplantation.
n Understand the physiology of the denervated, trans-
planted heart.
n Know the common adverse events and drug interac-
tions associated with immunosuppressive medications
used in patients following heart transplantation.
n Know the uses and limitations of techniques commonly
used to evaluate heart transplant patients for rejection
(clinical, echocardiogram, electrocardiogram, cardiac
catheterization, endomyocardial biopsy).
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7373.2.2.9. Genetics (12)
n Understand patterns of heritable cardiomyopathies.
n Understand genetic tests relevant to cardiomyopathies.
3.2.3. Evaluation and Documentation of Competence
All training programs should include written goals and
objectives for evaluation and care of patients with heart
failure with performance goals set according to the fel-
low’s level of training. These will serve as the basis for
formative feedback. A copy of these goals and objectives
should be supplied and explained to the trainee at the
onset of fellowship training and reviewed at the begin-
ning of each year. Evaluation of fellows should be per-
formed midway through, and at the completion of, each
rotation; evaluations should be directed toward whether
the fellow met those prespeciﬁed aims. The fellow eval-
uation should assess the fellow’s performance in each of
the 6 areas of core competencies, as appropriate for the
level of training, and should be based on direct observa-
tion of the fellow. Evaluation of competency in prepara-
tion, performance, and interpretation of the results of a
procedure should be given more consideration than a
focus on the number of procedures performed. Evaluation
of competency should be done in person with the trainee
and documented in the trainee’s fellowship record. If the
trainee is not progressing as expected, remedial actions
should be arranged and documented in accordance with
institutional procedures. All fellows should maintain a log
(preferably electronic) of all heart failure patients.
Trainees should participate in the care of at least 10 pa-
tients with advanced heart failure during the 3 years offellowship to ensure adequate clinical exposure and
enable sufﬁcient opportunities for assessment by the
clinical competency committees and their program
directors.
3.3. Advanced Training: Goals and Methods
Advanced training in pediatric heart failure and trans-
plantation requires a dedicated 12 months working with a
comprehensive pediatric advanced heart failure service.
The trainee should participate in the care of patients
receiving advanced medical therapies, mechanical assist
device support, and heart transplantation. The training
program should have a United Network for Organ
Sharing–approved pediatric transplantation program and
allow the trainees to gain sufﬁcient experience in the
management of pediatric transplant candidates and re-
cipients. All advanced trainees should have a rigorous
(bench, clinical, or translational) research training expe-
rience pertinent to advanced heart failure and trans-
plantation as part of (or prior to) their advanced training.
At the completion of the advanced training, the trainee
should undergo a competency assessment that estab-
lishes the ability to independently perform a compre-
hensive evaluation of a patient with advanced heart
failure, including an evaluation for heart transplantation.
The trainee should be able to formulate and execute a
treatment plan based on the evaluation in conjunction
with an advanced heart failure specialist. Clinical
competence should be assessed using a combination of
direct observation of clinical performance and structured
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